CDT Equity Sarborg stake valued at $127.5 million after $125,000-a-share subscription

Conduit Pharmaceuticals

Conduit Pharmaceuticals

CDT

0.00
  • CDT Equity flagged Sarborg’s share subscription by a New York private investment fund at USD 125,000 per share.
  • Transaction implied a fully diluted valuation of about USD 638.3 million for Sarborg.
  • CDT Equity holds 1,020 Sarborg shares, implying a stake value of about USD 127.5 million at the subscription price.
  • Proceeds earmarked for SarborgQ, a new quantum computing division tied to Sarborg’s Signature Intelligence platform.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CDT Equity Inc. published the original content used to generate this news brief on June 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.